SkinBioTherapeutics (‘SkinBio’, ‘the Company’) is an early mover in the microbiome skincare space, a rapidly growing market. The Company is developing a novel skincare treatment consisting of extracts taken from beneficial (‘probiotic’) bacteria. Their proprietary probiotic platform, SkinBiotix®, has completed preclinical studies and is expected to complete a human volunteer study in 2018.
19 Apr 2018
Initiation of Coverage
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Initiation of Coverage
SkinBioTherapeutics Plc (SBTX:LON) | 9.2 0 0.0% | Mkt Cap: 18.5m
- Published:
19 Apr 2018 -
Author:
Barry Gibb -
Pages:
27
SkinBioTherapeutics (‘SkinBio’, ‘the Company’) is an early mover in the microbiome skincare space, a rapidly growing market. The Company is developing a novel skincare treatment consisting of extracts taken from beneficial (‘probiotic’) bacteria. Their proprietary probiotic platform, SkinBiotix®, has completed preclinical studies and is expected to complete a human volunteer study in 2018.